These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

432 related articles for article (PubMed ID: 34237171)

  • 1. Increased fracture risk after discontinuation of anti-osteoporosis medications among hip fracture patients: A population-based cohort study.
    Fu SH; Wang CY; Hung CC; Lee CC; Yang RS; Huang CC; Farn CJ; Lin WH; Chen HM; Hsiao FY; Lin JW; Li CY
    J Intern Med; 2021 Dec; 290(6):1194-1205. PubMed ID: 34237171
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real world clinical outcomes when discontinuing denosumab or bisphosphonates in patients with surgically managed osteoporotic vertebral compression fractures: a population-based cohort study.
    Huang CC; Hung CC; Chen HM; Lin JW; Fu SH; Wang CY
    Spine J; 2024 Dec; 24(12):2366-2376. PubMed ID: 39154948
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-world effectiveness of anti-osteoporosis medications for the prevention of incident hip and clinical vertebral fractures in patients on long-term glucocorticoid therapy: A nationwide health insurance claims database study in Japan.
    Iki M; Fujimori K; Nakatoh S; Tamaki J; Ishii S; Okimoto N; Kamiya K; Ogawa S
    Bone; 2023 Jan; 166():116605. PubMed ID: 36347433
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of anti-fracture effectiveness of zoledronate, ibandronate and alendronate versus denosumab in a registry-based cohort study.
    Everts-Graber J; Bonel H; Lehmann D; Gahl B; Häuselmann H; Studer U; Ziswiler HR; Reichenbach S; Lehmann T
    Osteoporos Int; 2023 Nov; 34(11):1961-1973. PubMed ID: 37493978
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Denosumab treatment lapses, discontinuation, and off-treatment fracture risk: A retrospective study of patients with osteoporosis in a real-world clinical setting.
    Cruchelow KR; Peter ME; Chakrabarti A; Gipson HM; Gregory WT; DeClercq J; Choi L; Tanner SB
    Bone; 2023 Dec; 177():116925. PubMed ID: 37797711
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Time-varying exposure to anti-osteoporosis drugs and risk of first-time hip fracture: a population wide study within the Norwegian Epidemiologic Osteoporosis Studies (NOREPOS).
    Riska BSL; Gunnes N; Stigum H; Finnes TE; Meyer HE; Omsland TK; Holvik K
    Osteoporos Int; 2023 Aug; 34(8):1369-1379. PubMed ID: 37100950
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Duration of Bisphosphonate Drug Holidays and Associated Fracture Risk.
    Curtis JR; Saag KG; Arora T; Wright NC; Yun H; Daigle S; Matthews R; Delzell E
    Med Care; 2020 May; 58(5):419-426. PubMed ID: 31985584
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fracture risk following intermission of osteoporosis therapy.
    Dennison EM; Cooper C; Kanis JA; Bruyère O; Silverman S; McCloskey E; Abrahamsen B; Prieto-Alhambra D; Ferrari S;
    Osteoporos Int; 2019 Sep; 30(9):1733-1743. PubMed ID: 31175404
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of Risk of Osteoporotic Fracture in Denosumab vs Alendronate Treatment Within 3 Years of Initiation.
    Pedersen AB; Heide-Jørgensen U; Sørensen HT; Prieto-Alhambra D; Ehrenstein V
    JAMA Netw Open; 2019 Apr; 2(4):e192416. PubMed ID: 31002319
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Persistance and Compliance with Osteroporosis Therapies Among Women in a Commercially Insured Population in the United States.
    Cheng LI; Durden E; Limone B; Radbill L; Juneau PL; Spangler L; Mirza FM; Stolshek BS
    J Manag Care Spec Pharm; 2015 Sep; 21(9):824-33, 833a. PubMed ID: 26308229
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A systematic review and meta-analysis of the effect of bisphosphonate drug holidays on bone mineral density and osteoporotic fracture risk.
    Nayak S; Greenspan SL
    Osteoporos Int; 2019 Apr; 30(4):705-720. PubMed ID: 30623214
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Denosumab: a cost-effective alternative for older men with osteoporosis from a Swedish payer perspective.
    Parthan A; Kruse M; Agodoa I; Silverman S; Orwoll E
    Bone; 2014 Feb; 59():105-13. PubMed ID: 24231131
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Denosumab utilization among older adults in Ontario: patient characteristics, persistence with therapy, and return to therapy after an extended gap.
    Ban JK; Hao BB; McCarthy L; Guilcher SJT; Cadarette SM
    Osteoporos Int; 2019 Sep; 30(9):1865-1872. PubMed ID: 31317248
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative effectiveness and safety outcomes between denosumab and bisphosphonate in South Korea.
    Park C; Kim C; Park RW; Jeon JY
    J Bone Miner Res; 2024 Aug; 39(7):835-843. PubMed ID: 38722817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Refracture risk and all-cause mortality after vertebral fragility fractures: Anti-osteoporotic medications matter.
    Tai TW; Tsai YL; Shih CA; Li CC; Chang YF; Huang CF; Cheng TT; Hwang JS; Lu TH; Wu CH
    J Formos Med Assoc; 2023; 122 Suppl 1():S65-S73. PubMed ID: 37120337
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study.
    McClung MR; O'Donoghue ML; Papapoulos SE; Bone H; Langdahl B; Saag KG; Reid IR; Kiel DP; Cavallari I; Bonaca MP; Wiviott SD; de Villiers T; Ling X; Lippuner K; Nakamura T; Reginster JY; Rodriguez-Portales JA; Roux C; Zanchetta J; Zerbini CAF; Park JG; Im K; Cange A; Grip LT; Heyden N; DaSilva C; Cohn D; Massaad R; Scott BB; Verbruggen N; Gurner D; Miller DL; Blair ML; Polis AB; Stoch SA; Santora A; Lombardi A; Leung AT; Kaufman KD; Sabatine MS;
    Lancet Diabetes Endocrinol; 2019 Dec; 7(12):899-911. PubMed ID: 31676222
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative effectiveness of denosumab vs alendronate among postmenopausal women with osteoporosis.
    Curtis JR; Arora T; Liu Y; Lin TC; Spangler L; Brunetti VC; Stad RK; McDermott M; Bradbury BD; Kim M
    J Bone Miner Res; 2024 Aug; 39(7):826-834. PubMed ID: 38753892
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of medications on prevention of secondary osteoporotic vertebral compression fracture, non-vertebral fracture, and discontinuation due to adverse events: a meta-analysis of randomized controlled trials.
    Jin YZ; Lee JH; Xu B; Cho M
    BMC Musculoskelet Disord; 2019 Aug; 20(1):399. PubMed ID: 31472671
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Severe spontaneous vertebral fractures after denosumab discontinuation: three case reports.
    Aubry-Rozier B; Gonzalez-Rodriguez E; Stoll D; Lamy O
    Osteoporos Int; 2016 May; 27(5):1923-5. PubMed ID: 26510845
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiple Vertebral Fractures After Denosumab Discontinuation: FREEDOM and FREEDOM Extension Trials Additional Post Hoc Analyses.
    Cosman F; Huang S; McDermott M; Cummings SR
    J Bone Miner Res; 2022 Nov; 37(11):2112-2120. PubMed ID: 36088628
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.